Analyst Conference Summaries

Biotechnology Investor Aids

Syros Pharmaceuticals
SYRS

conference date: May 6, 2021 @ 5:30 AM Pacific Time

Syros Pharmaceuticals After the Orsenix Deal [December 29, 2020 at Seeking Alpha]

Syros Pharmaceuticals Update: Still a Buy [January 23, 2020 at Seeking Alpha]

Syros Pharmaceuticals Platform Undervalued [April 10, 2019 at Seeking Alpha]

2021
Syros
Pharmaceuticals
Q4 2020
Syros
Pharmaceuticals
Q1 2021
   
March 4, 2021 May 6, 2021    
2020
Syros
Pharmaceuticals
Q4 2019
Syros
Pharmaceuticals
Q1 2020
Syros
Pharmaceuticals
Q2 2020
Syros
Pharmaceuticals
Q3 2020
March 5, 2020 May 7, 2020 Aug. 6, 2020 Nov. 5, 2020

Syros Pharmaceuticals (SYRS) is a clinical-stage biotechnology company with a platform based on gene regulation.

Syros Pharmaceutical web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 GLYC
 INCY
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SGEN
 VBLT
 VSTM
 XLRN
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2021 William P. Meyers